Jean-Philippe Desilles, Ph.D., M.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Thrombectomy | 33 | 2022 | 673 | 3.680 |
Why?
|
| Brain Ischemia | 31 | 2022 | 3260 | 2.990 |
Why?
|
| Stroke | 47 | 2022 | 9256 | 2.490 |
Why?
|
| Intracranial Thrombosis | 6 | 2020 | 124 | 2.260 |
Why?
|
| Infarction, Middle Cerebral Artery | 11 | 2020 | 465 | 2.120 |
Why?
|
| Thrombolytic Therapy | 18 | 2022 | 2163 | 1.780 |
Why?
|
| Reperfusion | 8 | 2022 | 290 | 1.600 |
Why?
|
| Tissue Plasminogen Activator | 13 | 2022 | 1306 | 1.470 |
Why?
|
| Endovascular Procedures | 19 | 2022 | 1959 | 1.460 |
Why?
|
| Thrombosis | 10 | 2022 | 2840 | 1.170 |
Why?
|
| Blood-Brain Barrier | 4 | 2018 | 992 | 0.840 |
Why?
|
| Deoxyribonuclease I | 1 | 2020 | 229 | 0.760 |
Why?
|
| Fibrinolytic Agents | 11 | 2020 | 2129 | 0.720 |
Why?
|
| Venules | 1 | 2018 | 162 | 0.670 |
Why?
|
| Pia Mater | 1 | 2018 | 93 | 0.660 |
Why?
|
| Cerebral Hemorrhage | 6 | 2022 | 2518 | 0.630 |
Why?
|
| Cerebral Infarction | 4 | 2021 | 1039 | 0.630 |
Why?
|
| Registries | 13 | 2021 | 7989 | 0.610 |
Why?
|
| Microvessels | 2 | 2017 | 565 | 0.520 |
Why?
|
| Microcirculation | 1 | 2018 | 1301 | 0.480 |
Why?
|
| Intracranial Arteriovenous Malformations | 3 | 2020 | 391 | 0.460 |
Why?
|
| Cerebrovascular Circulation | 3 | 2018 | 2748 | 0.450 |
Why?
|
| Reperfusion Injury | 1 | 2019 | 1071 | 0.440 |
Why?
|
| Platelet Aggregation Inhibitors | 2 | 2021 | 2994 | 0.420 |
Why?
|
| Embolization, Therapeutic | 6 | 2021 | 1419 | 0.410 |
Why?
|
| Arterial Occlusive Diseases | 5 | 2020 | 836 | 0.390 |
Why?
|
| Diffusion Magnetic Resonance Imaging | 7 | 2020 | 2641 | 0.390 |
Why?
|
| Fibrinolysis | 2 | 2022 | 350 | 0.380 |
Why?
|
| Patient Admission | 2 | 2019 | 1398 | 0.380 |
Why?
|
| Blood Pressure | 8 | 2022 | 8528 | 0.360 |
Why?
|
| Intracranial Aneurysm | 4 | 2021 | 1342 | 0.360 |
Why?
|
| Treatment Outcome | 39 | 2022 | 61932 | 0.360 |
Why?
|
| Carotid Artery, Internal | 4 | 2020 | 473 | 0.350 |
Why?
|
| Hyperglycemia | 1 | 2017 | 1343 | 0.350 |
Why?
|
| Venous Thrombosis | 1 | 2018 | 1228 | 0.350 |
Why?
|
| Anterior Cerebral Artery | 2 | 2018 | 49 | 0.340 |
Why?
|
| Magnetic Resonance Angiography | 4 | 2020 | 1481 | 0.340 |
Why?
|
| Cerebral Angiography | 5 | 2021 | 1384 | 0.340 |
Why?
|
| Cerebral Revascularization | 3 | 2016 | 226 | 0.330 |
Why?
|
| Coronavirus Infections | 3 | 2020 | 3153 | 0.330 |
Why?
|
| Pneumonia, Viral | 3 | 2020 | 3275 | 0.320 |
Why?
|
| Carotid Stenosis | 3 | 2020 | 846 | 0.300 |
Why?
|
| Arteriovenous Fistula | 2 | 2020 | 300 | 0.300 |
Why?
|
| Blood Pressure Determination | 2 | 2020 | 607 | 0.280 |
Why?
|
| Adenosine Monophosphate | 3 | 2022 | 282 | 0.280 |
Why?
|
| Randomized Controlled Trials as Topic | 2 | 2020 | 9488 | 0.260 |
Why?
|
| Blood Glucose | 2 | 2019 | 6255 | 0.240 |
Why?
|
| Aged, 80 and over | 27 | 2022 | 58184 | 0.230 |
Why?
|
| Blood Platelets | 5 | 2021 | 2485 | 0.230 |
Why?
|
| Aged | 41 | 2022 | 161488 | 0.230 |
Why?
|
| Intracranial Hemorrhages | 4 | 2022 | 802 | 0.220 |
Why?
|
| Rats, Sprague-Dawley | 4 | 2018 | 8593 | 0.220 |
Why?
|
| Male | 51 | 2022 | 349524 | 0.220 |
Why?
|
| Inflammation | 2 | 2021 | 10019 | 0.210 |
Why?
|
| Collateral Circulation | 2 | 2020 | 311 | 0.210 |
Why?
|
| Middle Aged | 41 | 2021 | 213752 | 0.210 |
Why?
|
| Humans | 71 | 2022 | 708843 | 0.200 |
Why?
|
| Leukocytes | 3 | 2019 | 2095 | 0.200 |
Why?
|
| Severity of Illness Index | 3 | 2020 | 16008 | 0.200 |
Why?
|
| Sinus Thrombosis, Intracranial | 1 | 2021 | 102 | 0.190 |
Why?
|
| Rats | 6 | 2020 | 25094 | 0.190 |
Why?
|
| Stents | 4 | 2020 | 3312 | 0.190 |
Why?
|
| Carotid Artery Diseases | 2 | 2017 | 921 | 0.180 |
Why?
|
| Apolipoprotein A-I | 1 | 2020 | 287 | 0.180 |
Why?
|
| Hemostasis | 1 | 2021 | 454 | 0.170 |
Why?
|
| Female | 44 | 2022 | 375205 | 0.170 |
Why?
|
| Color | 1 | 2019 | 309 | 0.170 |
Why?
|
| France | 4 | 2020 | 459 | 0.160 |
Why?
|
| Embolism | 1 | 2020 | 388 | 0.160 |
Why?
|
| Magnetic Resonance Imaging | 10 | 2021 | 34151 | 0.160 |
Why?
|
| Aerosols | 1 | 2020 | 689 | 0.160 |
Why?
|
| Prospective Studies | 14 | 2021 | 50597 | 0.160 |
Why?
|
| Fibrin | 2 | 2019 | 516 | 0.160 |
Why?
|
| Phlebography | 1 | 2017 | 328 | 0.150 |
Why?
|
| Platelet Aggregation | 2 | 2020 | 814 | 0.150 |
Why?
|
| Intracranial Embolism | 1 | 2018 | 216 | 0.150 |
Why?
|
| Hypotension | 1 | 2021 | 822 | 0.150 |
Why?
|
| Disability Evaluation | 3 | 2019 | 1829 | 0.140 |
Why?
|
| Aneurysm, Ruptured | 1 | 2020 | 483 | 0.140 |
Why?
|
| Endocarditis | 1 | 2019 | 323 | 0.140 |
Why?
|
| Diabetes Mellitus | 1 | 2013 | 5348 | 0.140 |
Why?
|
| Time Factors | 12 | 2021 | 41038 | 0.130 |
Why?
|
| Antihypertensive Agents | 2 | 2022 | 2046 | 0.130 |
Why?
|
| Trachea | 1 | 2020 | 1076 | 0.130 |
Why?
|
| Blood Flow Velocity | 1 | 2018 | 1468 | 0.130 |
Why?
|
| Disease Models, Animal | 6 | 2021 | 18375 | 0.130 |
Why?
|
| Drug Resistance | 1 | 2019 | 1611 | 0.120 |
Why?
|
| Recombinant Proteins | 2 | 2020 | 6850 | 0.120 |
Why?
|
| Monitoring, Intraoperative | 1 | 2020 | 959 | 0.120 |
Why?
|
| Acute Disease | 2 | 2021 | 7158 | 0.120 |
Why?
|
| Thromboembolism | 1 | 2019 | 985 | 0.120 |
Why?
|
| Heparin | 1 | 2020 | 1625 | 0.120 |
Why?
|
| Radiography, Interventional | 1 | 2020 | 1096 | 0.120 |
Why?
|
| Hypertension | 3 | 2022 | 8161 | 0.110 |
Why?
|
| Patient Transfer | 1 | 2019 | 759 | 0.110 |
Why?
|
| Surgery, Computer-Assisted | 1 | 2020 | 1018 | 0.110 |
Why?
|
| Fibrinogen | 1 | 2015 | 914 | 0.110 |
Why?
|
| Radiosurgery | 1 | 2020 | 1352 | 0.110 |
Why?
|
| Intraoperative Complications | 1 | 2018 | 1192 | 0.100 |
Why?
|
| Image Processing, Computer-Assisted | 2 | 2018 | 8968 | 0.100 |
Why?
|
| Recovery of Function | 3 | 2019 | 2950 | 0.090 |
Why?
|
| Neutrophils | 2 | 2020 | 3867 | 0.090 |
Why?
|
| Hemorrhage | 1 | 2021 | 3235 | 0.090 |
Why?
|
| Retrospective Studies | 14 | 2021 | 71483 | 0.090 |
Why?
|
| Combined Modality Therapy | 3 | 2022 | 8896 | 0.090 |
Why?
|
| Tomography, X-Ray Computed | 5 | 2020 | 20308 | 0.090 |
Why?
|
| Animals | 8 | 2021 | 170486 | 0.090 |
Why?
|
| Disabled Persons | 1 | 2018 | 1154 | 0.090 |
Why?
|
| Lipoproteins, HDL | 1 | 2013 | 649 | 0.080 |
Why?
|
| Imaging, Three-Dimensional | 2 | 2020 | 3984 | 0.080 |
Why?
|
| Microscopy, Fluorescence | 1 | 2015 | 2836 | 0.080 |
Why?
|
| Catheters | 2 | 2020 | 347 | 0.080 |
Why?
|
| Cohort Studies | 5 | 2022 | 39292 | 0.080 |
Why?
|
| Heart Diseases | 1 | 2020 | 2759 | 0.080 |
Why?
|
| Pandemics | 3 | 2020 | 7089 | 0.070 |
Why?
|
| DNA | 1 | 2020 | 7172 | 0.070 |
Why?
|
| Referral and Consultation | 1 | 2019 | 3436 | 0.070 |
Why?
|
| Ischemic Attack, Transient | 1 | 2011 | 895 | 0.070 |
Why?
|
| Anticoagulants | 1 | 2020 | 4293 | 0.070 |
Why?
|
| Fluoroscopy | 2 | 2020 | 901 | 0.070 |
Why?
|
| Atherosclerosis | 1 | 2020 | 3228 | 0.070 |
Why?
|
| Cerebellum | 1 | 2011 | 1489 | 0.060 |
Why?
|
| Follow-Up Studies | 6 | 2021 | 39038 | 0.060 |
Why?
|
| Predictive Value of Tests | 4 | 2020 | 15252 | 0.060 |
Why?
|
| Angiotensins | 1 | 2022 | 131 | 0.050 |
Why?
|
| Odds Ratio | 3 | 2021 | 9754 | 0.050 |
Why?
|
| Superior Sagittal Sinus | 1 | 2021 | 17 | 0.050 |
Why?
|
| Triage | 2 | 2019 | 913 | 0.050 |
Why?
|
| Algorithms | 2 | 2020 | 13647 | 0.050 |
Why?
|
| Infarction, Posterior Cerebral Artery | 1 | 2020 | 13 | 0.050 |
Why?
|
| Infarction, Anterior Cerebral Artery | 1 | 2020 | 14 | 0.050 |
Why?
|
| Physicians | 1 | 2019 | 4292 | 0.050 |
Why?
|
| Paris | 1 | 2020 | 42 | 0.050 |
Why?
|
| Chi-Square Distribution | 2 | 2017 | 3562 | 0.050 |
Why?
|
| Erythrocytes | 2 | 2020 | 2418 | 0.050 |
Why?
|
| Plasminogen Activators | 1 | 2020 | 218 | 0.050 |
Why?
|
| Blood Cell Count | 1 | 2020 | 422 | 0.050 |
Why?
|
| Punctures | 1 | 2020 | 372 | 0.050 |
Why?
|
| Risk Factors | 7 | 2022 | 69553 | 0.050 |
Why?
|
| Suction | 1 | 2020 | 255 | 0.050 |
Why?
|
| Adult | 8 | 2021 | 211041 | 0.050 |
Why?
|
| Cerebral Veins | 1 | 2020 | 153 | 0.050 |
Why?
|
| Neutrophil Activation | 1 | 2020 | 229 | 0.040 |
Why?
|
| Heparin, Low-Molecular-Weight | 1 | 2020 | 318 | 0.040 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2012 | 3097 | 0.040 |
Why?
|
| Platelet Count | 1 | 2020 | 794 | 0.040 |
Why?
|
| Cerebral Arteries | 1 | 2020 | 497 | 0.040 |
Why?
|
| Microscopy, Electron, Scanning | 1 | 2019 | 1001 | 0.040 |
Why?
|
| Blood Coagulation Disorders | 1 | 2020 | 341 | 0.040 |
Why?
|
| Mortality | 2 | 2019 | 2732 | 0.040 |
Why?
|
| Postoperative Complications | 1 | 2019 | 15053 | 0.040 |
Why?
|
| Perfusion Imaging | 1 | 2018 | 189 | 0.040 |
Why?
|
| Hospital Mortality | 2 | 2020 | 5095 | 0.040 |
Why?
|
| Angiotensin Receptor Antagonists | 1 | 2022 | 823 | 0.040 |
Why?
|
| Single-Blind Method | 1 | 2020 | 1588 | 0.040 |
Why?
|
| von Willebrand Factor | 1 | 2019 | 663 | 0.040 |
Why?
|
| Patient Selection | 2 | 2018 | 4306 | 0.030 |
Why?
|
| Leukocyte Count | 1 | 2019 | 1670 | 0.030 |
Why?
|
| Rats, Wistar | 1 | 2019 | 2015 | 0.030 |
Why?
|
| Immunohistochemistry | 2 | 2019 | 11790 | 0.030 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 1 | 2022 | 1478 | 0.030 |
Why?
|
| Catheterization | 1 | 2020 | 1463 | 0.030 |
Why?
|
| Microsurgery | 1 | 2020 | 815 | 0.030 |
Why?
|
| Emergencies | 1 | 2020 | 1129 | 0.030 |
Why?
|
| Endpoint Determination | 1 | 2017 | 623 | 0.030 |
Why?
|
| Visual Fields | 1 | 2020 | 1026 | 0.030 |
Why?
|
| Streptococcus pneumoniae | 1 | 2019 | 780 | 0.030 |
Why?
|
| Rupture, Spontaneous | 1 | 2014 | 355 | 0.030 |
Why?
|
| Prognosis | 3 | 2019 | 28919 | 0.030 |
Why?
|
| Vision Disorders | 1 | 2020 | 1038 | 0.030 |
Why?
|
| Glycoproteins | 1 | 2021 | 2309 | 0.030 |
Why?
|
| Age Factors | 2 | 2020 | 18712 | 0.030 |
Why?
|
| Drug Administration Schedule | 1 | 2020 | 5045 | 0.030 |
Why?
|
| Aorta | 1 | 2020 | 2120 | 0.030 |
Why?
|
| Logistic Models | 2 | 2017 | 13468 | 0.030 |
Why?
|
| Middle Cerebral Artery | 1 | 2013 | 280 | 0.030 |
Why?
|
| Cardiac Imaging Techniques | 1 | 2014 | 266 | 0.030 |
Why?
|
| Staphylococcus aureus | 1 | 2019 | 1391 | 0.030 |
Why?
|
| Cerebrovascular Disorders | 1 | 2017 | 1508 | 0.030 |
Why?
|
| Feasibility Studies | 1 | 2020 | 4883 | 0.030 |
Why?
|
| Injections, Intravenous | 1 | 2013 | 1472 | 0.020 |
Why?
|
| Ischemia | 1 | 2019 | 1934 | 0.020 |
Why?
|
| Aspirin | 1 | 2020 | 3138 | 0.020 |
Why?
|
| Echocardiography, Transesophageal | 1 | 2014 | 1109 | 0.020 |
Why?
|
| Linear Models | 1 | 2017 | 5986 | 0.020 |
Why?
|
| Infusions, Intravenous | 1 | 2011 | 2303 | 0.020 |
Why?
|
| Double-Blind Method | 1 | 2019 | 11877 | 0.020 |
Why?
|
| Sensitivity and Specificity | 1 | 2020 | 14836 | 0.020 |
Why?
|
| Diagnosis, Differential | 1 | 2020 | 13274 | 0.020 |
Why?
|
| Young Adult | 2 | 2020 | 55940 | 0.010 |
Why?
|
| Brain | 2 | 2020 | 24969 | 0.010 |
Why?
|
| Case-Control Studies | 1 | 2020 | 21194 | 0.010 |
Why?
|
| Mice, Inbred C57BL | 1 | 2021 | 22989 | 0.010 |
Why?
|
| Adolescent | 2 | 2020 | 84718 | 0.010 |
Why?
|
| Echocardiography | 1 | 2014 | 5139 | 0.010 |
Why?
|
| Reproducibility of Results | 1 | 2019 | 19423 | 0.010 |
Why?
|
| Endothelium, Vascular | 1 | 2013 | 4658 | 0.010 |
Why?
|
| Cell Line | 1 | 2013 | 16657 | 0.010 |
Why?
|
| Mice | 1 | 2021 | 80876 | 0.010 |
Why?
|